1. Home
  2. CAPR vs TG Comparison

CAPR vs TG Comparison

Compare CAPR & TG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • TG
  • Stock Information
  • Founded
  • CAPR 2005
  • TG 1988
  • Country
  • CAPR United States
  • TG United States
  • Employees
  • CAPR N/A
  • TG N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • TG Metal Fabrications
  • Sector
  • CAPR Health Care
  • TG Industrials
  • Exchange
  • CAPR Nasdaq
  • TG Nasdaq
  • Market Cap
  • CAPR 324.6M
  • TG 301.0M
  • IPO Year
  • CAPR N/A
  • TG 1989
  • Fundamental
  • Price
  • CAPR $6.28
  • TG $7.84
  • Analyst Decision
  • CAPR Strong Buy
  • TG
  • Analyst Count
  • CAPR 8
  • TG 0
  • Target Price
  • CAPR $24.75
  • TG N/A
  • AVG Volume (30 Days)
  • CAPR 1.4M
  • TG 89.4K
  • Earning Date
  • CAPR 08-11-2025
  • TG 08-08-2025
  • Dividend Yield
  • CAPR N/A
  • TG N/A
  • EPS Growth
  • CAPR N/A
  • TG N/A
  • EPS
  • CAPR N/A
  • TG N/A
  • Revenue
  • CAPR $13,392,150.00
  • TG $643,014,000.00
  • Revenue This Year
  • CAPR N/A
  • TG N/A
  • Revenue Next Year
  • CAPR $6,061.53
  • TG N/A
  • P/E Ratio
  • CAPR N/A
  • TG N/A
  • Revenue Growth
  • CAPR N/A
  • TG 28.10
  • 52 Week Low
  • CAPR $3.98
  • TG $5.86
  • 52 Week High
  • CAPR $23.40
  • TG $9.43
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 36.33
  • TG 46.37
  • Support Level
  • CAPR $6.17
  • TG $7.68
  • Resistance Level
  • CAPR $7.30
  • TG $8.03
  • Average True Range (ATR)
  • CAPR 0.43
  • TG 0.20
  • MACD
  • CAPR -0.11
  • TG 0.06
  • Stochastic Oscillator
  • CAPR 4.53
  • TG 75.00

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About TG Tredegar Corporation

Tredegar Corp, through its subsidiaries, engages in the manufacture of polyethylene plastic films, polyester films, and aluminum extrusions. Polyethylene plastic films produce plastic films, elastics, and laminate materials that are used in personal care products, surface protection films, and specialty and optical lighting applications. The company operates through segments including PE films, flexible packaging films, and aluminum extrusions. Aluminum extrusions generate the majority of revenue and provide high-quality, soft-alloy, medium-strength aluminum utilized in the building and construction, automotive, consumer durables, machinery and equipment, electrical, and distribution markets. Revenue is generated from the United States, Asia, and Brazil.

Share on Social Networks: